NINDS Advisory Council Meeting Minutes, May 24, 2018

NINDS Advisory Council Meeting Minutes, May 24, 2018

Department of Health and Human Services
Public Health Service
National Institutes of Health
National Advisory Neurological Disorders and Stroke Council

Summary of Meeting1
May 24, 2018

The National Advisory Neurological Disorders and Stroke (NANDS) Council was convened for its 202nd meeting on May 24, 2018, in the Neuroscience Center Building (NSC), Conference Room C/D/E, in Rockville, Maryland.  Dr. Walter Koroshetz, Director of the National Institute of Neurological Disorders and Stroke (NINDS), served as Chairperson.

In accordance with Public Law 92-463, the meeting was:

Open:    May 24, 2018:  8:00 a.m. to 2:00 p.m. for the review and discussion of program development, needs, and policy; and

Closed:  May 24, 2018:  2:00 p.m. to 4:45 p.m. for the consideration of individual grant applications.

Council members present:
Dr. Laurence Abbott
Dr. Issam Awad
Dr. Amy Brooks-Kayal
Dr. Karen Chen
Dr. Hollis Cline
Dr. Beverly Davidson
Dr. David Hackney
Ms. Janet Hieshetter
Dr. Karen Johnston
Dr. Bruce Ovbiagele
Dr. Steve Perrin
Dr. Indira Raman
Dr. Steven Roberds
Dr. S. Lawrence Zipursky (via telephone)

Ex officio member present:
Colonel Sidney Hinds, II, Department of Defense
Christopher Bever, Jr., M.D., Department of Veteran Affairs

Ad hoc attendees present:
Ms. Susan Dickinson

Council Roster (Attachment 1)

Members of the public present for portions of the open meeting included:

Ronald Bartek, Friedreich’s Ataxia Research Alliance
Philip Goglas II, Dystonia Medical Research Foundation
Sheila Harley, BETA
André Porter, American Society for Biochemistry and Molecular Biology

Federal attendees are listed at the end of these minutes.

I.  Call to Order and Opening Remarks

Dr. Koroshetz welcomed Council members, visitors, and staff to the 202nd meeting of the National Advisory Neurological Disorders and Stroke Council. 

II.  Report of the Director, Division of Extramural Research, NINDS

Approval of Council Minutes—Dr. Finkelstein requested, and the Council voted approval of the February 1, 2018, Council meeting minutes.

The following future Council meeting dates were confirmed:

Thursday, September 13, 2018

Thursday, February 14, 2019 – updated date

Thursday, May 23, 2019

Thursday, September 5, 2019

Thursday, February 6, 2020

Thursday May 28, 2020

Thursday September 10, 2020

Expedited Review Process—Each Council round, a subset of Council members approves applications in advance of the meeting with scores within the payline.  This expedited review process focuses on applications for which there are no unresolved issues.  Dr. Finkelstein thanked Council members Beverly Davidson, Janet Hieshetter, and David Gutmann for handling this responsibility for this meeting and the fiscal year.  For the current Council round, 167 applications were eligible to be expedited. Ninety-five (95) of these awards already have been issued, and the others will be issued shortly after Council.

Extramural Announcements

Dr. Finkelstein introduced William Daley, Ph.D., from the Neural Environment Cluster.
Dr. Clinton Wright introduced Cristina Saugar Lanchas, Ph.D., from the Division of Clinical Research.
Dr. Amir Tamiz introduced Rebecca (Becky) Roof, Ph.D., from the Division of Translational Research.
Dr. Amy Adams introduced Alissa Gallagher, from the Office of Scientific Liaison.

III.  Report of the Director, NINDS

Dr. Walter Koroshetz, Director, NINDS

NIH and NINDS Budget—Dr. Koroshetz provided an overview of the NIH and NINDS budgets. He noted that neuroscience is now the largest area of NIH funding, which is distributed across 25 of its ICs. The Fiscal Year (FY) 2018 Omnibus Bill represented a 6.4 percent increase to the NINDS budget. NINDS received funding for the Helping to End Addiction Long-Term (HEAL) pain initiative (which will be apportioned across NIH ICs) and the Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative®. Distribution of the NINDS budget remains similar to past years, with 83 percent allocated to extramural investigators, 9.6 percent to intramural, 4.1 percent to managing the Institute, and, as mandated by Congress, 3.2 percent to Small Business Innovation Research (SBIR) and Small Business Technology Transfer Research (STTR) awards. In FY2018, NINDS is funding approximately 294 more grants than in FY2014, despite rising costs per grant.

Diversity Funding Trends—Dr. Koroshetz reported an upward trend in funding for diversity supplements and career development awards. The new NIH Blueprint Diversity Specialized Predoctoral to Postdoctoral Advancement in Neuroscience (D-SPAN) builds on Blueprint investments in undergraduate diversity training and encourages retention of outstanding, diverse graduate students who have demonstrated ability and interest in careers as independent neuroscience researchers.

Leadership Changes—Dr. Richard Nakamura is retiring as Director of the Center for Scientific Review, and Dr. James Battey is retiring as Director of the National Institute on Deafness and Communication Disorders. Dr. Koroshetz welcomed three new members to the NANDS Council—Drs. Hollis Cline, David B. Hackney, and Karen Johnston—and acknowledged the service of retiring Council members Drs. Amy Brooks-Kayal, Karen Chen, Timothy Coetzee, Beverly Davidson, and S. Lawrence Zipursky.

NINDS Leadership Searches—A candidate has been identified for the NINDS Scientific Director position, final interviews have been completed for the NINDS Director of Neuroscience position, and the search committee has recommended a short list of candidates for Director of the BRAIN Initiative. NINDS is also seeking a Scientific Review Officer to focus on the BRAIN Initiative, six program directors, and two medical officers.

All of Us—The recently launched All of Us Program aims to enroll 1 million people living in the United States to accelerate research and improve health. Participants provide medical history and lifestyle information and may be asked to visit a local enrollment center to have blood pressure, height, and weight measurements taken, donate biosamples, or participate in targeted research programs.

The NINDS Research Program (R35) Award—The R35 is designed to create stable funding for outstanding investigators toward facilitating longer-range, high-risk research. These eight-year awards provide up to $750,000 per year direct costs and require a commitment of at least 50 percent of the investigator’s effort. With the current solicitation, released in May, NINDS will prioritize selecting a diverse pool of investigators for this award with respect to scientific approach, area of study, career stage, and background.

Special Council Review—NINDS announced modifications to its Special Council Review policy for support of research from well-funded investigators, effective for applications reviewed at the January 2019 Council. Well-funded researchers are those with NIH research support exceeding $1 million in direct costs at the time of the Council meeting, including the pending application. Applications from well-funded investigators will be reviewed for funding consideration based on the new NINDS SCR policy.

Myalgic Encephalomyelitis and Chronic Fatigue Syndrome (ME/CFS)—NINDS leads a trans-NIH ME/CFS working group that coordinates ME/CFS research efforts at NIH. The cause of ME/CFS and strategies to treat it remain unknown. A workshop tentatively titled “Accelerating Research on ME/CFS” is planned for spring 2019 to advance research in the field.

Senate Appropriations Committee Hearing— On May 17th, the Senate Appropriations Subcommittee on Labor, Health and Human Services, Education, and Related Agencies held a hearing on the NIH Budget.  NIH Director Dr. Francis Collins testified, accompanied by NIAID Director Dr. Anthony Fauci, NIA Director Dr. Richard Hodes, NCI Director Dr. Ned Sharpless, NINDS Director Dr. Walter Koroshetz, and NIDA Director Dr. Nora Volkow. Members of Congress acknowledged NIH’s contribution to advancing science and biomedical research and are supportive of contributing resources to the NIH mission.

The Opioid Epidemic—Dr. Koroshetz and NINDS staff visited the Huntington Healthcare Center in Huntington, WV to gain further insight on the effects of the opioid epidemic in rural communities.  They visited Lily’s Place, a neonatal abstinence syndrome center, where infants born to addicted mothers are treated in a special opioid detoxification unit, and where mothers are provided supportive services to help end their addiction.

The HEAL Initiative —In April 2018, NIH launched the HEAL (Helping to End Addiction Long-term) Initiative, a trans-agency effort to speed scientific solutions to stem the national opioid public health crisis. More than 42,000 Americans died of opioid overdose in 2016 and over 2 million Americans live with addiction to opioids. To address this national crisis, $500 million in the Fiscal Year 2018 Consolidated Appropriations Act, was appropriated to NIH.  The primary focus of NINDS under this initiative is on preventing addiction through enhanced pain management, and improving treatments for opioid misuse disorder and addiction. In February, NINDS Council approved concepts for biomarker discovery and development, and a clinical trial network. NINDS leads the NIH Pain Consortium, which aims to enhance pain research and promote collaboration across NIH. The Consortium will host “At the Intersection of Chronic Pain Management and the Opioid Crisis” at NIH on May 31 and June 1.

NINDS Contributions to Approved Therapies—A new feature on the NINDS website highlights the role of NINDS in paths of discovery for FDA-approved therapies for neurological disorders.

NINDS Research Advances

  • Mapping Cell-Type Diversity in Developing Brain—Two recent papers highlighted a cutting-edge, high-throughput, single-cell process that disassociates, sorts, and labels brain cells and then sequences them to obtain a transcriptome signature. Nowakowski et al. described excitatory neurons in different cortical areas, and Mayer et al. identified inhibitory interneuron subtypes.
  • Real-Time Observation of Brain Healing: NINDS intramural scientists are studying how meninges react to light mechanical stimuli using Intravital 2-photon microscopy for real-time observation of mouse blood vessels being damaged and then repaired after mild traumatic brain injury. Specific immune cells involved in healing have been identified.
  • CRISPR Finds Genetic Suspects Behind ALS/FTS Subtype: A research team used CRISPR-Cas9 to identify modifiers of mutant C9ORF72 toxicity in human cells. Further testing in motor neurons from amyotrophic lateral sclerosis (ALS) patients showed that blocking TMX2 increased cell survival.
  • Panel Recommends FDA Approval of Cannabis-derived Epilepsy Drug: The NINDS Epilepsy Therapy Screening Program (ETSP) is evaluating Cannabidiol in animal models of treatment-resistant epilepsy.
  • Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT)—The POINT Trial found that combining Clopidogrel and aspirin reduced risk of ischemic attack and ischemic vascular death, but increased risk of major hemorrhage compared with aspirin during a 90-day treatment after acute minor ischemic stroke or transient ischemic attack.  Doctors must balance the bleeding risks with the benefit of decrease risk of stroke.

BRAIN Initiative Update—Recent BRAIN accomplishments include a wide-field microscopy technique that enables scientists to observe never-before-seen neuronal firing patterns. The 4th Annual BRAIN Initiative Principal Investigators (PI) meeting included discussion of next steps and new collaborations, a media training session, and interviews conducted by local high school students. Now that BRAIN has completed the first five years of its ten-year plan, a working group of the Advisory Council to the NIH Director is reviewing progress and updating the plan.

IV.  The MD Care Act

Dr. Glen Nuckolls
Neurogenetics Cluster

Dr. Heather Rieff
NINDS Office of Science Policy and Planning

Muscular Dystrophy (MD) is a group of rare, genetic diseases that lead to progressive degeneration of muscle tissue due to defects in muscle fibers and replacement of muscle tissue by fat or fibrous connective tissue. The MD CARE Act directed NIH to coordinate MD research activities and authorized the Wellstone MD Research Centers. As a result, NIH is involved in advancing the Action Plan for the Muscular Dystrophies which entails better understanding the disease, accelerating the development of treatments and reducing disease burden. Dr. Rieff indicated that the Wellstone Centers will undergo a program evaluation to identify best practices and recommendations to enhance the program. A request for information will be released to obtain input from key stakeholders.

V.  NINDS Funding Overview

Dr. Amy Adams
Office of Scientific Liaison

Dr. Adams outlined the purpose of the NINDS Funding Strategy that explains to the public and other stakeholders how NINDS makes funding priorities and allocates its resources. The strategy page on the NINDS website includes the NINDS budget, success rate, payline, and key policies. Dr. Adams described the desire of the Institute to increase transparency and present information in a more useful, engaging, and interactive way for scientists, advocates, and the public. She illustrated ways to convey different types of information on the NINDS website to better inform stakeholders about funding policies.

Council discussed ways to tailor the information of interest to various target audiences.

VI.  Update from the Scientific Director of Intramural Research

Dr. Alan Koretsky
Scientific Director, NINDS

Dr. Koretsky presented an overview of the NINDS Intramural Research Program (IRP). Since 2008, the program budget has increased by $15 million for science, with other increases going to salary support and maintaining research facilities.

Dr. Koretsky indicated the program has supported 15 intramural K99/R00 awards, 1 NIH Director Transition to Independence Award, and 6 assistant clinical investigator appointments. The Program currently has a total of 115 professional staff. Dr Koretsky will step down from his position as Scientific Director and will be returning to the lab.

VII.  Update from the NIMH

Dr. Joshua Gordon
Director, NIMH

NIMH is the lead federal agency for research on mental illnesses and supports over 3,000 research grants and contracts as well as 600 scientists in its intramural research program. The Institute aims to transform understanding and treatment of mental illnesses through basic and clinical research.

NIMH’s short-term research priorities include identifying implementable evidence-based practices and knowledge gaps for suicide prevention. Suicides have been steadily on the rise for the past 15 years and may be underreported, as opioid overdoses are not classified as a suicide unless a suicide note is found. A medium-term goal is development of technologies to interrogate neural circuits to improve understanding and treatment of mental health disorders; advances have included identification of a circuit mechanism for differentiating positive and negative associations in a mouse model that has therapeutic potential. Translation to humans will require neurobiologic and technological approaches. A long-term NIMH research priority involves applying theoretical and computational approaches to psychiatry—biophysical modeling, computational phenotyping, and the use of data mining. Dr. Gordon noted that modeling neural systems and further understanding the diverse genetic and environmental factors that contribute to mental illness will improve psychiatric care.

Council members discussed with Dr. Gordon pathways and mechanisms of depression that are co-morbid with neurological illnesses and interventions underlying resiliency.

VIII. Initiatives Requiring Concept Clearance

  1. Comparing Effectiveness Research in Clinical Neuroscience

    Dr. Adam Hartman,
    Division of Clinical Research

    To leverage support to effect changes in clinical practice, NINDS is proposing a new funding opportunity announcement (FOA) to support comparative effectiveness approaches. CER is defined as “research comparing the benefits and harms of different existing interventions and strategies to prevent, diagnose, treat, and monitor health conditions in real-world settings.” These studies approximate randomized controlled trials (RCTs) in methodology but are much less expensive than RCTs. The proposed funding opportunity aims to encourage grant applications for investigator-initiated comparative effectiveness research using the phased UG3/UH3 cooperative funding mechanism.

    Council commended NINDS on the rigor and in-depth understanding of CER. Some members raised concerns about lack of appropriate use of the CER methodology by researchers and suggested NINDS consider providing investigators with a tool box of CER best practices.

    Council voted to approve concept clearance for the proposed FOA.
     
  2. Discover and Validate Novel Targets for Safe and Effective Pain Treatment

    Dr. Michael Oshinsky
    Systems and Cognitive Neuroscience Cluster

    Dr. Oshinsky described opportunities to advance basic research for the discovery of novel targets that can be used to treat pain. To support this research, NINDS is proposing a funding opportunity supplement to the biomarker discovery program NINDS Council approved in February. The supplement would provide additional funds to awardees for validation of novel targets for safe and effective pain treatment. The announcement and associated funding would occur in FY18. Further funding announcements will be released in FY19 with receipt dates and awards being made in the same fiscal year.

    Council discussed options of providing multi-year supplements and indicated support for this. 

    Council voted to approve concept clearance for the proposed supplement.
     
  3. Platform Screen Program for Pain (PSPP)

    Dr. John Kehne
    Division of Translational Research

    Dr. Kehne described a proposed initiative to establish a preclinical testing platform to identify and profile non-addictive therapeutics for pain. The program will complement the National Center for Advancing Translational Sciences platform that focuses on in vitro resources to advance translation. The intention is to make these resources available at no cost to researchers in academic and industry laboratories who may have promising leads that they would like to test in the program. NINDS plans to start the contracting process and make awards in 2019. NINDS is proposing a 5-year program and if it is successful, may consider extending it.

    Council discussed the types of models that would be used to screen for acute versus chronic pain treatments and the entry criteria for potential applicants. NINDS described its portfolio of programs that would support the translational research needs of this platform. Some members indicated it would be beneficial to broaden the number of animal models used for compound screening to expand the categories of analgesic used as therapeutics for pain treatment. NINDS indicated a workshop is being held in the fall to address these matters.

    Council voted to approve concept clearance for the proposed initiative.

  4. Music and Health

    Dr. Robert Riddle
    Neurogenetics Cluster

    NIH, in partnership with the John F. Kennedy Center for the Performing Arts, and the National Endowment for the Arts, established the Sound Health initiative to increase understanding of how music affects health and to explore ways to enhance the potential for music as therapy for neurological disorders. As a result, a trans-NIH Working Group developed potential FOAs supporting R01s and R21s entitled “Music and the Brain: Research Across the Lifespan.” Dr. Riddle outlined that the aim of these FOAs is to increase understanding of how music can affect health, with an emphasis on what happens at the neuroscience level, and potential clinical applications. Projects can propose basic mechanistic studies, translational research, and/or exploratory clinical studies. Institutes across NIH will contribute funds to study applications of music in health.

    Council voted to approve concept clearance for the proposed network.

IX.  Council Consideration of Pending Applications

This portion of the meeting, involving specific grant review, was closed to the public. The Council gave special attention to applications from foreign institutions and other applications requiring specific discussion. Prior to discussion of the grants, Dr. Finkelstein reminded Council members regarding conflict of interest and confidentiality.

Conflict of Interest—Regulations concerning conflict of interest were reviewed. Council members were reminded that materials furnished for review purposes and discussion during the closed portions of the meeting are considered privileged information. All Council members present signed a statement certifying that they had not been involved in any conflict-of-interest situations during the review of grant applications.

Confidentiality—During the closed session, any information that is discussed and the outcome of any recommendation are considered privileged information. They may not be discussed outside of the closed session. If an applicant requests support for his or her application from a Council member, the Council member must respond that he/she is not permitted to discuss the application. Any inquiry should be referred to Dr. Robert Finkelstein, NINDS Advisory Council Executive Secretary, who then will refer the question to the appropriate staff member for response.

Research Training and Career Development Programs – The Council reviewed a total of 350 research career development and institutional training grant applications with primary assignment to NINDS, and 202 of them (57.7 percent) were scored in the amount of $14.01 million first-year direct costs. It is anticipated that, of the research career development and institutional training grant applications competing at this Council, NINDS will be able to pay first-year direct costs of approximately $5.23 million (80 grants).

Research Project and Center Awards – The Council reviewed a total of 1,736 research project and center applications with primary assignment to NINDS, and 985 of them (56.7 percent) were scored/percentiled in the amount of $334.7 million first-year direct costs. It is anticipated that, of the research grants competing at this Council, NINDS will be able to pay first-year direct costs of approximately $90 million (328 grants).

Senator Jacob Javits Neuroscience Investigator Awards – The Senator Jacob Javits Neuroscience Investigator Awards are made to distinguished investigators who have a record of scientific excellence and productivity, who are actively pursuing an area of research of strategic importance, and who can be expected to continue to be highly productive for a seven-year period. Candidates are nominated and selected at each Council meeting. Council approved one Javits nomination at this meeting: Jerrold L. Vitek, M.D., Ph.D. (University of Minnesota).

Small Business Innovation Research and Small Business Technology Transfer Award Programs – The Council reviewed a total of 121 Small Business Innovation Research (SBIR) and Small Technology Transfer Award (STTR) grant applications with primary assignment to NINDS, and 72 of them (59.5 percent) were scored in the amount of $23.9 million first-year direct costs. It is anticipated that, of the SBIR and STTR applications competing at this Council, NINDS will be able to pay first-year direct costs of approximately $8.6 million (27 grants).

X.  Review of the Division of Intramural Research Board of Scientific Counselors' Reports

Dr. Alan Koretsky, Scientific Director, Division of Intramural Research, NINDS

This portion of the meeting, to review and evaluate the Division of Intramural Research Board of Scientific Counselors’ Reports, was closed to the public.

XI.  Adjournment

The meeting was adjourned at 5:05 p.m. on Thursday, May 24, 2018.

NINDS employees present for portions of the meeting included:

Dr. Amy Adams
Dr. Deborah Babcock
Ms. Kelly Baker
Dr. Francesca Bosetti
Dr. Chris Boshoff
Dr. Patrick Bellgowan
Dr. Bill Benzing
Dr. Andrew Breeden
Dr. Jeremy Brown
Mr. Ryan Calabrese
Ms. Dana Camak
Mr. Roger Campbell
Dr. Emily Carifi
Ms. Stacey Chambers
Dr. Daofen Chen
Ms. Janice Cordell
Dr. Roderick Corriveau
Dr. Devon Crawford
Dr. Diana Cummings
Dr. Charles Cywin
Dr. Will Daley
Dr. Karen David
Dr. Tijuanna Decoster
Dr. Kristin Dupre
Dr. Edgardo Falcon
Ms. Stephanie Fertig
Dr. Robert Finkelstein
Dr. Jane Fountain
Ms. Alissa Gallagher
Ms. Marie Gill
Dr. Jim Gnadt
Dr. Maureen Gormley
Dr. Amelie Gubitz
Dr. Mohamed Hachicha
Ms. Preeti Hans
Dr. Janet He
Ms. Monique Hill
Dr. Andrew Hooper
Dr. Nina Hsu
Dr. Lyn Jakeman
Dr. Scott Janis
Dr. Sophia Jeon
Dr. David Jett
Dr. Michelle Jones-London
Mr. Kevin Kallmes
Dr. John Kehne
Dr. Brian Klein
Dr. Jim Koenig
Dr. Alan Koretsky
Dr. Steve Korn
Dr. Walter Koroshetz
Dr. Doe Kumsa
Dr. Pascal Laeng
Ms. Christine Lam
Dr. Cristina Saugar Lanchas
Dr. Miriam Leenders
Dr. Cara Long
Dr. Codrin Lungu
Ms. Quynh Ly
Dr. Ernie Lyons
Ms. Tammy Magid
Dr. Linda McGavern
Ms. Barbara McMakin
Dr. Carolina Mendoza-Puccini
Dr. Meghan Mott
Dr. Daniel Miller
Dr. Jill Morris
Ms. Pam Morrison
Dr. Birgit Neuhuber
Dr. Glen Nuckolls
Dr. Ana Olariu
Ms. Oreisa O'Neil-Mathurin
Dr. Michael Oshinsky
Dr. David Owens
Dr. Katie Pahigiannis
Ms. Josabeth Paredes
Dr. Mary Ann Pelleymounter
Dr. Leah Pogorzala
Dr. Shamsi Raeissi
Dr. Robert Riddle
Dr. Heather Rieff
Dr. Becky Roof
Dr. Cheryse Sankar
Dr. Joel Saydoff
Dr. Alisa Schaefer
Dr. Nina Schor
Dr. Paul Scott
Ms. Shalini Sharma
Dr. Beth-Anne Sieber
Dr. Shai Silberberg
Dr. Andrew Skinner
Dr. Shardell Spriggs
Dr. Randall Stewart
Dr. Natalia Strunnikova
Dr. Christine Swanson-Fisher
Dr. Ned Talley
Dr. Amir Tamiz
Dr. Anna Taylor
Dr. Carol Taylor-Burds
Dr. Michael Tennekoon
Dr. Natalie Trzcinski
Dr. Lauren Ullrich
Dr. Ursula Utz
Dr. Jackie Ward
Ms. Margo Warren
Dr. Elizabeth Webber
Dr. Letitia Weigand
Dr. Samantha White
Dr. Ling Wong
Dr. May Wong
Dr. Clinton Wright
Dr. Robert Zalutsky

Other federal employees present for portions of the meeting included:

Dr. Joseph Breen, NIAID
Dr. Alexei Kondratyev, CSR
Dr. Paul Sato, OAR
Dr. Elyse Schauwecker, CSR
Dr. Laurent Taupenot, CSR
Dr. Brian Tian, CSR
Dr. Ken Wiley, NHGRI
Dr. Wei-Qin Zhao, CSR


We certify that, to the best of our knowledge, the foregoing minutes and attachments are accurate and complete.

 

______
Date

_____________________________
Robert Finkelstein, Ph.D.
Executive Secretary
National Advisory Neurological Disorders
and Stroke Council

Director, Division of Extramural Research
National Institute of Neurological Disorders
and Stroke

______
Date
_____________________________
Walter Koroshetz, M.D.
Chairperson
National Advisory Neurological Disorders
and Stroke Council

Director
National Institute of Neurological Disorders
and Stroke

These minutes will be formally considered by the Council at its next meeting.  Corrections or notations will be incorporated in the minutes of that meeting.


1For the record, it is noted that members absent themselves from the meeting when the Council is discussing applications (a) from their respective institutions or (b) in which a real or apparent conflict of interest might occur.